Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Legal / IP

Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software

Fineline Cube Apr 4, 2026
Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Fineline Cube Apr 4, 2026
Company Deals

Zhifei Biological Renews Exclusive China Distribution Pact with Merck for Gardasil 9, Rotateq, and Pneumovax—Shifts to Demand-Driven Supply Model

Fineline Cube Apr 3, 2026
Company Deals Digital

Xellar Biosystems Closes RMB 200M Series A Led by China Life Investment to Build 3D Bio Intelligence Platform

Fineline Cube Apr 3, 2026
Company Deals

Regeneron Partners with TriNetX in $200M Deal to Expand World-Leading Genomic-Phenotypic Data Platform

Fineline Cube Apr 3, 2026
Policy / Regulatory

China’s CDE Releases 105th Batch of Reference Preparations for Generic Drug Evaluation, Adds 8 New Drugs

Fineline Cube Apr 2, 2026
Company Drug

Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent

Fineline Cube Apr 4, 2026
Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Fineline Cube Apr 4, 2026
Company Drug

US FDA Approves HutchMed and Takeda’s Fruzaqla for Metastatic Colorectal Cancer Treatment

Fineline Cube Nov 9, 2023

The US Food and Drug Administration (FDA) has granted approval to HutchMed (NASDAQ: HCM) and...

Company Deals

Suzhou Porton Biologics Partners with BioMap to Enhance AAV Vector Design in Gene Therapy

Fineline Cube Nov 9, 2023

Suzhou Porton Biologics Ltd, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into...

Company Deals

CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships

Fineline Cube Nov 9, 2023

The 6th China International Import Expo (CIIE) held in Shanghai this week has been a...

Company Deals

Zymeworks and BeiGene Terminate Licensing Agreement for ZW49 ADC

Fineline Cube Nov 8, 2023

Zymeworks Inc. (NASDAQ: ZYME), a Canada-based biotech company, has announced in its Q3 financial report...

Company Deals

Worg Pharmaceuticals Expands into Spain with Acquisition of Diater for EUR 150 Million

Fineline Cube Nov 8, 2023

Worg Pharmaceuticals, a Hangzhou-based developer of allergic drugs, has formally entered the Spanish market by...

Company Drug

Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial

Fineline Cube Nov 8, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of...

Company

Gilead Reports Q3 2023 Financials with 1% YOY Revenue Increase and Updates 2023 Outlook

Fineline Cube Nov 8, 2023

Gilead (NASDAQ: GILD) has released its financial results for the third quarter of 2023, showing...

Company Deals

AstraZeneca Expands China Presence with Over 30 Agreements at CIIE

Fineline Cube Nov 8, 2023

At the 6th China International Import Expo (CIIE) in Shanghai, UK-based pharmaceutical giant AstraZeneca plc...

Company

Moderna Initiates Construction of First China-Based Pharmaceutical Plant in Shanghai

Fineline Cube Nov 8, 2023

S-based mRNA specialist, Moderna (NASDAQ: MRNA), has commenced construction on its inaugural pharmaceutical facility in...

Company Deals

Senti Biosciences and Celest Therapeutics Partner on CAR-NK Cell Therapy Clinical Trial in China

Fineline Cube Nov 8, 2023

Senti Biosciences Inc., (NASDAQ: SNTI), a San Francisco-based biotech company, has announced a strategic collaboration...

Company Deals

Eisai Partners with Shanghai Pharmaceuticals for Alzheimer’s Drug Leqembi in China

Fineline Cube Nov 8, 2023

Eisai (TYO: 4523), a Japan-headquartered pharmaceutical company, has entered into a significant partnership with Shanghai...

Company Deals

Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China

Fineline Cube Nov 8, 2023

Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a...

Company Drug

Abbisko Therapeutics Receives FDA Approval for Phase I Study of FGFR4 Inhibitor ABSK012

Fineline Cube Nov 8, 2023

Shanghai-based biotech company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Company Deals Medical Device

Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology

Fineline Cube Nov 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based...

Policy / Regulatory

9th National Volume-Based Procurement Round Results in 70% Price Reduction for 41 Drugs

Fineline Cube Nov 7, 2023

The results of the 9th round of China’s national volume-based procurement (VBP) program have been...

Company Deals

Qingdao’s Raise Care Secures Over RMB 100 Million in Series B Financing Led by CITIC Capital

Fineline Cube Nov 7, 2023

Qingdao-based Raise Care has reportedly secured upwards of RMB 100 million (USD 13.7 million) in...

Company Drug

Chengdu Kanghong Pharmaceutical’s KH629 Receives FDA Approval for NASH Clinical Trial

Fineline Cube Nov 7, 2023

Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a China-based pharmaceutical company, has announced that...

Company

FibroGen Inc. Reports 155% YOY Sales Increase in Q3 2023 Financial Results

Fineline Cube Nov 7, 2023

US-based biotechnology company FibroGen Inc., (NASDAQ: FGEN) has reported its financial results for the third...

Company Deals

GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal

Fineline Cube Nov 7, 2023

GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...

Company Drug

Gilead Sciences and Arcus Biosciences Announce Positive Phase II Data for Domvanalimab Combination Therapy

Fineline Cube Nov 7, 2023

Gilead Sciences (NASDAQ: GILD) and Arcus Biosciences (NYSE: RCUS) have this week released preliminary data...

Posts pagination

1 … 427 428 429 … 646

Recent updates

  • Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software
  • Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent
  • Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
  • Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline
  • Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Legal / IP

Siemens Healthineers Partners with Shanghai’s Ruijin Hospital on World’s First AI-Powered Liver Fat Quantification Software

Company Drug

Zhuhai Rundu’s Higenamine Receives NMPA Approval as China’s First Category 1 Cardiac Stress Test Agent

Company Drug

Youcare Pharma’s YKYY018 Inhalation Therapy Expands to COVID-19 Clinical Study Following RSV Development Success

Company Deals

Binhui Biopharmaceutical Submits Hong Kong IPO Prospectus with Pioneering Oncolytic Virus Pipeline

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.